Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

David W. Dodick; Richard B. Lipton; Michel D. Ferrari; Peter J. Goadsby; Douglas McCrory; F. Michael Cutrer; Paul Williams

doi:10.1007/s11916-004-0064-2

Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

David W. Dodick, Richard B. Lipton, Michel D. Ferrari, Peter J. Goadsby, Douglas McCrory, F. Michael Cutrer, Paul Williams

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.

Original language	English (US)
Pages (from-to)	435-442
Number of pages	8
Journal	Current pain and headache reports
Volume	8
Issue number	6
DOIs	https://doi.org/10.1007/s11916-004-0064-2
State	Published - Dec 2004
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology
Anesthesiology and Pain Medicine

Access to Document

10.1007/s11916-004-0064-2

Cite this

@article{ae96622f7fbf404cb6070c89da95b733,

title = "Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.",

abstract = "Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.",

author = "Dodick, {David W.} and Lipton, {Richard B.} and Ferrari, {Michel D.} and Goadsby, {Peter J.} and Douglas McCrory and Cutrer, {F. Michael} and Paul Williams",

year = "2004",

month = dec,

doi = "10.1007/s11916-004-0064-2",

language = "English (US)",

volume = "8",

pages = "435--442",

journal = "Current pain and headache reports",

issn = "1531-3433",

publisher = "Current Science, Inc.",

number = "6",

}

TY - JOUR

T1 - Prioritizing treatment attributes and their impact on selecting an oral triptan

T2 - results from the TRIPSTAR Project.

AU - Dodick, David W.

AU - Lipton, Richard B.

AU - Ferrari, Michel D.

AU - Goadsby, Peter J.

AU - McCrory, Douglas

AU - Cutrer, F. Michael

AU - Williams, Paul

PY - 2004/12

Y1 - 2004/12

N2 - Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.

AB - Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=16544394399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544394399&partnerID=8YFLogxK

U2 - 10.1007/s11916-004-0064-2

DO - 10.1007/s11916-004-0064-2

M3 - Review article

C2 - 15509456

AN - SCOPUS:16544394399

SN - 1531-3433

VL - 8

SP - 435

EP - 442

JO - Current pain and headache reports

JF - Current pain and headache reports

IS - 6

ER -

Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this